Corpus ID: 6169824

Large Molecule Therapeutics Preclinical Evaluation of Multistep Targeting of Diasialoganglioside GD 2 Using an IgG-scFv Bispeci fi c Antibody with High Af fi nity for GD 2 and DOTA Metal Complex

@inproceedings{Cheal2014LargeMT,
  title={Large Molecule Therapeutics Preclinical Evaluation of Multistep Targeting of Diasialoganglioside GD 2 Using an IgG-scFv Bispeci fi c Antibody with High Af fi nity for GD 2 and DOTA Metal Complex},
  author={S. Cheal and H. Xu and Hongfen Guo and P. Zanzonico and S. Larson and N. Cheung},
  year={2014}
}
Bispecific antibodies (BsAb) haveproven to beuseful targeting vectors for pretargeted radioimmunotherapy (PRIT). We sought to overcome key PRIT limitations such as high renal radiation exposure and immunogenicity (e.g., of streptavidin–antibody fusions), to advance clinical translation of this PRIT strategy for diasialoganglioside GD2-positive [GD2(þ)] tumors. For this purpose, an IgG-scFv BsAbwas engineered using the sequences for the anti-GD2humanizedmonoclonal antibodyhu3F8 andC825, amurine… Expand

Figures and Tables from this paper

References

SHOWING 1-10 OF 30 REFERENCES
Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2.
  • N. Cheung, S. Modak, +9 authors S. Larson
  • Chemistry, Medicine
  • Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • 2004
A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance.
Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging.
89Zr-DFO-J591 for ImmunoPET of Prostate-Specific Membrane Antigen Expression In Vivo
Biodistribution and Clearance of Small Molecule Hapten Chelates for Pretargeted Radioimmunotherapy
...
1
2
3
...